CP 001

Drug Profile

CP 001

Alternative Names: CP001

Latest Information Update: 11 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Caelus Health
  • Developer Caelus Health; Johnson & Johnson Innovation
  • Class Antihypoglycaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Metabolic syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 05 Jan 2017 Caelus Health enters into a collaboration with Johnson & Johnson Innovation for the development of CP-001
  • 05 Jan 2017 Phase-I clinical trials in Metabolic syndrome in Netherlands prior to January 2017 (PO) (Caelus Health Pipeline January 2017)
  • 05 Jan 2017 Phase-I clinical trials in Type-2-diabetes mellitus prevention in Netherlands prior to January 2017 (PO) (Caelus Health Pipeline January 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top